[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"west-nile-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:west-nile-virus":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,115,168,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":84,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537",false,"NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.",true,"ALL","2 Years","75 Years",{"count":21,"type":22},10000,"ESTIMATED","OBSERVATIONAL","RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":105,"type":106},"2026-01-22","ACTUAL",{"date":108,"type":106},"2025-12-18",{"date":110,"type":22},"2027-09-30",{"name":112,"class":113},"Institut Pasteur du Cambodge","OTHER",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":143,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":114},"100582154","serological-measurement-of-montpellier-professionals-contacts-with-infectious-agents-responsible-for-animal-borne-diseases-100582154","NCT06859619","Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.","SEZAM","Inclusion Criteria:\n\n* Age 18 or over\n* Consultant in an infectious diseases department\n* Have given written consent to participate in the study\n* Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.\n\nExclusion Criteria:\n\n* \\- Pregnant and breast-feeding women\n* Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)\n* Participants who are not fluent in French and who do not have a support person capable of reading French.\n* Persons unable to express their consent.\n* Persons participating in another research project with an exclusion period still in progress.\n* Persons not affiliated to a social security scheme or not benefiting from such a scheme.","18 Years",{"count":125,"type":22},183,"INTERVENTIONAL",[128],"NA","Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.\n\nThe aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.\n\nDescribing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.",[75,38,36,37,131,132,133,134,135,136,35,137,138,139,30,140,141,142],"Rickettsiosis","Tularemia","Psittacosis","Lyme Disease","Tick-borne Encephalitis","Hantaviral Infection Nos","Dengue Virus","Zika Virus","Chikungunya Virus Infection","Usutu Virus","Toscana Virus","Crimean-Congo Haemorrhagic Fever Virus",[144,38,36,145,146,147,148,149,150,151,152,153,154,155,132,133,156,157],"Leishmaniasis,","Zika virus","Q fever, Rickettsiosis","Lyme disease","Tick-borne encephaliti","Hantavirus","Hepatitis E virus","Dengue virus","Chikungunya virus","West-Nile virus","Usutu virus","Toscana virus","Crimean-Congo haemorrhagic fever virus","epidemiology","NOT_YET_RECRUITING","2025-02-27",{"date":161,"type":106},"2025-03-05",{"date":163,"type":22},"2025-03-03",{"date":165,"type":22},"2025-10-03",{"name":167,"class":113},"University Hospital, Montpellier",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":126,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":114},"100565321","investigating-visuo-spatial-abilities-and-psychological-effects-in-west-nile-and-multiple-sclerosis-patients-with-a-focus-on-a-possible-rehabilitation-protocol-100565321","NCT06640660","Investigating Visuo-spatial Abilities and Psychological Effects in West Nile and Multiple Sclerosis Patients with a Focus on a Possible Rehabilitation Protocol","Visuomind","Inclusion Criteria:\n\n* Diagnosis of: Multiple Scleroris OR vWN infection ascertained by laboratory analysis and received no later than twelve months prior to the date of hospitalization\n* preserved use of at least one hand\n* normal or corrected to normal vision\n\nExclusion Criteria:\n\n* history of psychiatric and\u002For concurrent neurological diseases\n* inability to provide informed consent,\n* impaired comprehension of oral instructions,","20 Years","85 Years",{"count":178,"type":22},50,[128],"The study aims to investigate visuospatial abilities and psychological outcomes in patients with multiple scleroris (MS) and patients with West Nile virus infection (vWN). Patients will undergo a specific neuropsychological and psychological evaluation. Afterwards, patients will receive 10 sessions of cognitive training integrating digital exercises and prismatic lenses. At the end of the treatment, patients will be re-evaluated to explore for potential changes in the cognitive and psychological profile.",[182,30],"Multiple Sclerosis",[184,185,186],"neurological patients","cognitive training","neuropsychology","2024-10-11",{"date":189,"type":106},"2024-10-15",{"date":191,"type":106},"2022-09-21",{"date":193,"type":22},"2024-12-30",{"name":195,"class":113},"IRCCS San Camillo, Venezia, Italy",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":126,"phases":204,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":114},"100555310","phase-2-early-interferon-beta-treatment-for-west-nile-virus-infection-100555310","NCT06510426","Early Interferon-beta Treatment for West-Nile Virus Infection","Diagnosis of WNV infection will be based on the following:\n\n1. Patients with clinical presentation suspected as compatible with WNV infection, with symptoms including elevated fever, headache or flaccid paralysis or fever with encephalopathy.\n\n   And:\n2. Positive anti-WNV IgM serology \u002F WNV PCR from either serum, urine or CSF.\n\nInclusion criteria:\n\nWe aim to focus on three patients' populations:\n\n1. Patients older than 70 years of age, who are at higher risk for the presence of neutralizing anti-Type I IFN auto-antibodies, and therefore at higher risk for developing severe neuroinvasive disease. Only patients who fulfill the diagnostic criteria above will be included.\n2. Patients presenting with neuroinvasive WNV disease, including either flaccid paralysis or encephalitis, independent of their age, excluding a presentation consistent with isolated aseptic meningitis (headache, fever, 6th nerve palsy). Only patients who fulfill the diagnostic criteria above will be included.\n3. Immunocompromised patients at any age. Immunocompromised patients will be defined as patients with hematologic malignancy (treated or untreated); chemotherapy within previous 4 weeks, stem cell transplant recipient or solid organ transplant recipient; use of any immunosuppressant drug including prednisone greater than or equal to 20 mg\u002Fday within the previous 4 weeks; primary \u002F acquired immunodeficiency disorder. Only patients who fulfill the diagnostic criteria above will be included.\n\nExclusion Criteria:\n\n1. Patients younger than 18 years old.\n2. Pregnant women.\n3. Contraindication for the administration of the drug: Hypersensitivity to natural or recombinant interferon beta, and decompensated liver disease.\n4. A patient with neuroinvasive disease showing consistent spontaneous improvement over a period of \\> 2 days and mRS of below 4.\n5. More than 8 days from onset of neurological symptoms in immunocompetent patients and more than 10 days in immunocompromised patients. This time frame will be renewed if a patient with flaccid paralysis develops new onset encephalitis.\n6. Patients who are receiving active chemotherapy treatment or suffer concurrent severe viral infection.",{"count":203,"type":22},100,[205],"PHASE2","West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease.\n\nDespite that, in minority of cases (\\~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease).\n\nRecent study has shown that up to 40% of WNV patients who develop neuroinvasive disease, have antibodies against Interferons (anti-Type I interferon autoantibodies), which neutralizes interferons, and could explain the development of severe disease.\n\nThe investigators therefore assume that early treatment with interferon beta (the type of interferon against which most patients do not have neutralizing antibodies) could prevent the development of severe neuroinvasive WNV disease.",[30,208,209,210],"West Nile Fever Encephalitis","West Nile Fever Myelitis","West Nile Fever With Other Complications",[30,212,213,214,215],"WNV","Encephalitis","Flaccid paralysis","WNV neuroinvasive disease","2024-07-20",{"date":218,"type":106},"2024-07-23",{"date":220,"type":106},"2024-07-14",{"date":222,"type":22},"2025-12-31",{"name":224,"class":225},"Tel-Aviv Sourasky Medical Center","OTHER_GOV"]